Analysts Offer Insights on Healthcare Companies: Lipocine (NASDAQ: LPCN) and Zynerba Pharmaceuticals (NASDAQ: ZYNE)

By Jason Carr

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lipocine (NASDAQ: LPCN) and Zynerba Pharmaceuticals (NASDAQ: ZYNE).

Lipocine (NASDAQ: LPCN)

In a report released yesterday, Dewey Steadman from Canaccord Genuity maintained a Hold rating on Lipocine (NASDAQ: LPCN), with a price target of $2. The company’s shares opened today at $1.49, close to its 52-week low of $1.15.

According to TipRanks.com, Steadman is ranked 0 out of 5 stars with an average return of -5.7% and a 40.3% success rate. Steadman covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, ANI Pharmaceuticals Inc, and Pacira Pharmaceuticals.

Lipocine has an analyst consensus of Moderate Buy, with a price target consensus of $5.33.

Zynerba Pharmaceuticals (NASDAQ: ZYNE)

Canaccord Genuity analyst Arlinda Lee maintained a Buy rating on Zynerba Pharmaceuticals (NASDAQ: ZYNE) yesterday and set a price target of $18. The company’s shares opened today at $10.53.

According to TipRanks.com, Lee is a 4-star analyst with an average return of 9.2% and a 48.6% success rate. Lee covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Actinium Pharmaceuticals, and Asterias Biotherapeutics.

Currently, the analyst consensus on Zynerba Pharmaceuticals is Strong Buy and the average price target is $20.42, representing a 93.9% upside.

In a report issued on March 5, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $17 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.